Highbridge Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Highbridge Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,670	Closed	-$163K	–	1848
2017 Q2	$163K	Sell	11,670 -23,146	-66%	-$341K	﹤0.01%	1139
2017 Q1	$594K	Buy	34,816 +19,139	+122%	+$230K	0.01%	820
2016 Q4	$161K	Buy	15,677 +4,967	+46%	+$45.4K	﹤0.01%	1161
2016 Q3	$108K	Buy	+10,710	New	+$117K	﹤0.01%	1243
2015 Q1	–	Sell	-17,880	Closed	-$238K	–	1638
2014 Q4	$238K	Buy	+17,880	New	+$231K	﹤0.01%	1022

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Highbridge Capital Management's CNCE Position: Q3 2017 in Review

Highbridge Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017, closing a stake of 11,670 shares — an estimated $163K sold.

Highbridge Capital Management first reported a position in CNCE in Q4 2014 and held it in 5 quarters. The position peaked at $594K in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

Highbridge Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 11,670 Concert Pharmaceuticals, Inc. shares in Q3 2017, an estimated $163K.
Highbridge Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
Highbridge Capital Management's Concert Pharmaceuticals, Inc. position peaked at $594K in Q1 2017.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.